- Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
- Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Ultimovacs ASA – Annual General Meeting held on April 18, 2024
- Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
- Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
- Ultimovacs – Invitation to Business Update on April 17, 2024
- Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
- Ultimovacs ASA: Mandatory notification of trade by primary insider
More ▼
Key statistics
On Thursday, Ultimovacs ASA (ULTI:OSL) closed at 7.35, 21.09% above the 52 week low of 6.07 set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.50 |
---|---|
High | 7.67 |
Low | 7.32 |
Bid | 7.35 |
Offer | 7.38 |
Previous close | 7.40 |
Average volume | 512.89k |
---|---|
Shares outstanding | 34.41m |
Free float | 23.73m |
P/E (TTM) | -- |
Market cap | 254.60m NOK |
EPS (TTM) | -5.17 NOK |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼